Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Equivalence Study of ONS-3010 vs Humira in Moderate to Severe Plaque Psoriasis
2015-004614-26Phase 3Completed
- Sponsor
- Outlook Therapeutics
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing ONS-3010 arm with Humira arm (2 arms). Primary endpoint: PASI 75 response at Week 17. Started May 2016; status: completed.
02
Drugs
adalimumabONS-3010
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2015-004614-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004614-26.